{"product_id":"aqst-swot-analysis","title":"(AQST) Aquestive Therapeutics, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aquestive Therapeutics, Inc. SWOT Analysis summarizes the company’s core products (transdermal, oral film, and specialty CNS therapies), their uses, and a structured review of strengths, weaknesses, opportunities, and threats—shown here as a real preview of the product. The page includes a genuine sample so you can assess style and substance; purchase the full version to download the complete, ready-to-use SWOT report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4 commercialized products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics has 4 commercialized products: Sympazan, Suboxone, Zuplenz, and Azstarys. That gives it revenue-linked exposure across epilepsy, opioid dependence, nausea and vomiting, and ADHD. A broader base reduces dependence on one product and helps spread commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral, sublingual, and buccal film expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. is built on proprietary film-based drug delivery, with oral soluble, sublingual, and buccal films at the core of its model. That format can improve convenience and adherence for patients who struggle with tablets or capsules, especially in fast-use or swallowing-difficulty settings. It also gives Company Name a differentiated platform for reformulating drugs into patient-friendly doses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e7 named products and candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. shows strength in 7 named programs across marketed products, pipeline assets, and prior work, including Libervant, Exservan, AQST-108, AQST-305, AQST-109, and KYNMOBI. That breadth points to repeatable formulation and development skill, not a one-off asset. It also gives the company more shots at approvals and revenue across multiple 2025-2026 programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFocus on unmet medical needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. focuses on unmet needs in seizures, ALS, acromegaly, and severe allergic reactions, where current treatment options can be slow, invasive, or hard to use. That target mix can support clinical relevance and stronger pricing power if products win approval and adoption. It also keeps the pipeline aimed at high-need specialty markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets clear treatment gaps\u003c\/li\u003e\n\u003cli\u003eFits specialty, high-value markets\u003c\/li\u003e\n\u003cli\u003eSupports pricing if adopted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. and international market presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics operates in the U.S. and international markets, so it is not tied to one demand pool. That reach can widen the addressable market for launches like Anaphylm and support country-by-country partnerships, which lowers dependence on a single channel. It also gives the Company more room to time launches where reimbursement and regulatory timing are strongest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader launch runway.\u003c\/li\u003e\n\u003cli\u003eMore partner options.\u003c\/li\u003e\n\u003cli\u003eLess single-market risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive's 4 Products and 7 Programs Power 2025-2026 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics has 4 commercialized products and 7 named programs, so it has more than one revenue and pipeline path. Its film-based oral, sublingual, and buccal delivery platform supports 2025-2026 launches in high-need areas like epilepsy, opioid dependence, ADHD, and anaphylaxis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial products\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed programs\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery platform\u003c\/td\u003e\n\u003ctd\u003eFilm-based\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Aquestive Therapeutics, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick SWOT snapshot for Aquestive Therapeutics, Inc. to simplify strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography of primary industry reports, FDA filings, and financial statements to speed due diligence and verify key claims about Aquestive Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnly 4 commercial products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. still relies on only 4 commercial products, so its marketed base is narrow. That makes total revenue more exposed to one product’s sales, pricing, or launch timing. It also leaves the Company with fewer steady cash-generating assets than larger peers, which can keep funding pressure high if one product underperforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline-heavy profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. is still a pipeline-heavy story: 5 key assets—Libervant, Exservan, AQST-108, AQST-305, and AQST-109—remain in development, so value still hinges on trial, FDA, and launch execution. Until approvals land, pipeline risk stays high, and any delay can push cash burn and revenue timing. That makes 2025-2026 milestones the main driver of upside, not current earnings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty indications only\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. leans on specialty-only targets like Lennox-Gastaut syndrome, ALS, and acromegaly, each with small patient pools; for example, ALS affects about 5 per 100,000 people, while acromegaly is roughly 60 per 1 million. That limits peak sales versus mass-market drugs, so growth depends on several niche wins, not one blockbuster. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDependence on novel dosage forms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s film-based dosing is a clear edge, but it also makes execution harder because each product needs tight control of thickness, drug load, and release. Regulators will test bioavailability, consistency, and usability closely, with bioequivalence often judged against the 80%-125% range, so even small batch drift can delay approval or launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFilm dosing adds manufacturing complexity.\u003c\/li\u003e\n\u003cli\u003eRegulators focus on bioavailability and consistency.\u003c\/li\u003e\n\u003cli\u003eSmall production issues can slow adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHistory since 2004 without scale leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFounded in 2004, Aquestive Therapeutics, Inc. still operates as a small pharma player more than 20 years later, so its long runway has not yet translated into scale leadership. That gap points to a slow commercial build and tighter resources than bigger rivals. In sales, marketing, and capital access, larger drug makers usually have a clear edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounded in 2004; still not scale-leading\u003c\/li\u003e\n\u003cli\u003eMore than 20 years to build size\u003c\/li\u003e\n\u003cli\u003eFaces weaker reach than big pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFew Products, Narrow Markets, and Big Approval Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. has a thin base: only 4 commercial products, while 5 key assets are still in development, so 2025-2026 value still depends on approvals and launches. Its niche focus also caps scale: ALS affects about 5 per 100,000 people and acromegaly about 60 per 1 million. Film dosing adds manufacturing risk, and its small size limits sales reach and cash power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial base\u003c\/td\u003e\n\u003ctd\u003e4 products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003e5 key assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALS prevalence\u003c\/td\u003e\n\u003ctd\u003e5 per 100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAquestive Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it summarizes Aquestive Therapeutics' strengths, weaknesses, opportunities, and threats with actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibervant seizure treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibervant is Aquestive Therapeutics, Inc.'s diazepam buccal soluble film for seizure treatment, aimed at a real acute-care gap in epilepsy. The U.S. has about 3.4 million people with epilepsy, and a non-oral option can help patients who cannot swallow during a seizure. If uptake grows, Libervant could add a differentiated, convenient rescue option in a market where speed and ease of use matter most.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-109 oral epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-109 is Aquestive Therapeutics, Inc.'s oral epinephrine program for anaphylaxis, a market where fast use matters and current auto-injectors still face training, timing, and needle barriers.\u003c\/p\u003e\n\u003cp\u003eThe U.S. sees about 1 in 50 people affected by food allergy, and anaphylaxis remains a recurring emergency, so an oral option could widen real-world use and improve access.\u003c\/p\u003e\n\u003cp\u003eIf approved, AQST-109 could create a new epinephrine category and add a large commercial lane beyond the current device-led market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-108 systemic epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-108, a sublingual epinephrine film, could open a new growth lane beyond anaphylaxis and expand Aquestive Therapeutics, Inc.’s reach into other systemic uses. That matters because the platform is already commercialized, so one delivery system could support more than one therapy. If approved in additional indications, it could add revenue without starting from zero.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAQST-305 acromegaly treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAQST-305 is a sublingual octreotide film for acromegaly, a rare disease affecting about 60 people per 1 million. That small pool can support specialty pricing and focused sales, especially with 7-year U.S. orphan exclusivity.\u003c\/p\u003e\n\u003cp\u003eIf Aquestive Therapeutics, Inc. wins launch traction, AQST-305 could expand revenue beyond its current core oral and rescue products and add a higher-value endocrine franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare-disease pricing supports margins\u003c\/li\u003e\n\u003cli\u003eFocused launch lowers commercial waste\u003c\/li\u003e\n\u003cli\u003eSuccess broadens Aquestive Therapeutics, Inc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational expansion of film products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. already sells in U.S. and international markets, so it can push existing film products into new geographies without building a new platform. That can lift revenue faster through local partners and regulatory wins, especially if international approvals mirror U.S. demand for thin-strip therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses current products, not new R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eAdds revenue with partner deals\u003c\/li\u003e\n\u003cli\u003eScales faster after approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive’s Film Platform Targets Big, Underserved Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpportunities for Aquestive Therapeutics, Inc. center on turning its film platform into multiple products: Libervant, AQST-109, AQST-108, and AQST-305. With 3.4 million U.S. epilepsy patients, about 1 in 50 people affected by food allergy, and acromegaly at roughly 60 per 1 million, the addressable need is real. A wider label and new geographies could add revenue without rebuilding the core platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e3.4M U.S. patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood allergy\u003c\/td\u003e\n\u003ctd\u003e1 in 50 people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcromegaly\u003c\/td\u003e\n\u003ctd\u003e60 per 1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory approval risk is high because Aquestive Therapeutics, Inc.’s pipeline still depends on clinical success and FDA review. For oral epinephrine, any request for more data, label limits, or non-approval could push back revenue and keep cash burn elevated. That matters even more for first-in-category drugs, where the approval bar is higher and timelines can slip fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from established therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. faces entrenched branded and generic rivals in epilepsy, nausea, opioid dependence, ADHD, Parkinson’s, and allergy care. With generics filling about 90% of U.S. prescriptions, prescribers often stick to familiar, lower-cost options. Switching costs, prior auth, and formulary hurdles can slow uptake and cap share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric and pricing pressure remains a key threat for Aquestive Therapeutics, Inc. Suboxone Film has faced generic competition since 2019, and mature oral and transmucosal products often see lower net pricing as payers push rebates and reimbursement cuts. Even if volume holds, weaker net price can still compress gross margin and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical development failure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical development failure is a major threat for Aquestive Therapeutics, Inc. because its growth depends on a small set of pipeline programs. If one key candidate slips in testing or review, the Company can lose a large part of its future revenue upside. That risk is sharper for small biotechs, where one setback can move valuation fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew pipeline shots drive growth\u003c\/li\u003e\n\u003cli\u003eOne failure cuts upside fast\u003c\/li\u003e\n\u003cli\u003eSmall caps feel pipeline risk more\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and access challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturing is a real threat for Aquestive Therapeutics, Inc. because its film formulations need tight production controls and steady supply, so any batch issue or delay can hit output fast. Novel dosage forms can also face slower payer coverage and pharmacy adoption, which can delay patient starts and weaken sales momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized film production raises supply risk.\u003c\/li\u003e\n\u003cli\u003ePayer coverage can slow pharmacy access.\u003c\/li\u003e\n\u003cli\u003eAny disruption can stall commercial growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a company built on new delivery forms, even a short manufacturing or reimbursement break can push revenue timing back.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Risk and Generic Pressure Keep Aquestive’s Growth Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. still faces high FDA and clinical risk: one setback on oral epinephrine or any lead program can delay revenue and lift cash burn. Generic pressure is also tough, with about 90% of U.S. prescriptions filled by generics, so pricing and access can stay weak. Manufacturing and payer hurdles can slow starts and stall growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric pressure\u003c\/td\u003e\n\u003ctd\u003e~90% U.S. Rx are generics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuboxone Film\u003c\/td\u003e\n\u003ctd\u003eGeneric competition since 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233976295689,"sku":"aqst-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/aqst-swot-analysis.webp?v=1785711256","url":"https:\/\/dcfanalyst.com\/products\/aqst-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}